Por acuerdo del Consejo de Administración de Alternative Gene Expression S.L. (en lo sucesivo “Algenex”) se convoca Junta General Extraordinaria de socios de Haizea, que tendrá lugar en Madrid, en las oficinas de Cleon Capital, Calle Serrano número 76 – 5 Izda., 28006 Madrid, el día 11 de septiembre de 2019, a las 17:00 horas.
Spanish biotechnology firm Algenex has progressed to its next stage of development after securing approximately €4 million ($4.5 million) in investment.
Animal Health Investment Europe is a premier international investment forum. The event was held on February 26th and 27th in London. More than 60 companies applied to participate in the Showcase, but only 24 were finalists, among whom was ALGENEX. The finalists, hand-picked by the Selection Committee, introduced themselves and their products/services on the main stage, in a quick-fire round of presentations. Claudia Jiménez, General Manager of ALGENEX, explained the CrisBio® technology, which consists in natural bio-reactors which have unique advantages for industrial production of any kind of recombinant protein, offering the most simple, cost-effective and scalable production technology up to date. CrisBio® has multiple advantages to obtain biotechnological high-tech products, with respect to classical production based on bioreactors. Related links Animal Health Event CrisBio® technology